Minyu Zhang

Dr. Minyu Zhang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZZZiwei Zhou
Ziwei Zhou
MLMeijing Li
Meijing Li
ZZZekuan Zhang
Zekuan Zhang
ZSZhimin Song
Zhimin Song
JXJingjing Xu
Jingjing Xu
MGMuxin Gong
Muxin Gong

Verified
Journal Article
Open access
PDF file
MZMinyu Zhang
Minyu Zhang
LXLiping Xu
Liping Xu
HYHongjun Yang
Hongjun Yang
Neurological diseases (NDs) are a leading cause of death worldwide and tend to mainly affect people under the age of 50. High rates of premature death and disability caused by NDs undoubtedly constrain societal development. However, effective therapeutic drugs and methods are very limited. Schisandra chinensis Fructus (SCF) is the dry ripe fruit of Schisandra chinensis (Turcz.) Baill, which has been used in traditional Chinese medicine for thousands of years. Recent research has indicated that SCF and its active ingredients show a protective role in NDs, including cerebrovascular diseases, neurodegenerative diseases, or depression. The key neuroprotective mechanisms of SCF and its active ingredients have been demonstrated to include antioxidation, suppression of apoptosis, anti-inflammation, regulation of neurotransmitters, and modulation of brain-derived neurotrophic factor (BDNF) related pathways. This paper summarizes studies of the role of SCF and its active ingredients in protecting against NDs, and highlights them as promising resources for future treatment. Furthermore, novel insights on the future challenges of SCF and its active ingredients are offered.

25 May 2017 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
MZMinyu Zhang
Minyu Zhang
HWHongwei Wu
Hongwei Wu
FGFeifei Guo
Feifei Guo
YYYangyang Yu
Yangyang Yu
JWJunying Wei
Junying Wei
HYHongjun Yang
Hongjun Yang
Traditional Chinese medicine (TCM) preparations have significant effects on some refractory diseases; however, these compositions are complex and their mechanisms are unknown. Identification of the active components in these preparations is essential. The mortality rate for heart failure (HF) has been increasing in recent years, and myocardial dysfunction (MD) has been proved to be the pathological basis of HF. Yixinshu Capsule (YXSC) is a multi-component oral drug with therapeutic effects on HF. However, the key active components are still unclear. In this study, YXSC intestinal absorption liquid (IAL) was used and 62 compounds were identified by an analytical chemistry approach. Then, a compound – target – function network was established with a bioinformatics analysis tool. Finally, a cell model of MD on human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) was used to verify the therapeutic effects of the active components of YXSC. Schisandrin A (Sch A) and schisandrin B (Sch B) were demonstrated to be the active components of YXSC by attenuating endothelin-1 (ET-1)-induced contraction dysfunction, brain natriuretic peptide (BNP) content elevation, and the morphological changes of hiPS-CMs. For the first time, our data illustrate the potent protective effects of Sch A and Sch B on ET-1-induced dysfunctional hiPS-CMs and revealed their effective targets and pathways. The integrative approach used in our study was applied to identify active components in TCM preparations and excavate the possible mechanisms.

22 March 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YLYuting Long
Yuting Long
YLYuman Li
Yuman Li
ZMZaina Ma
Zaina Ma
YXYonghao Xie
Yonghao Xie
HZHui Zhao
Hui Zhao
RLRenhui Liu
Renhui Liu

30 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ZWZhou zi Wei
Zhou zi Wei
ZSZhimin Song
Zhimin Song
XGXiaomeng Guo
Xiaomeng Guo
QWQi Wang
Qi Wang
MLMeijing Li
Meijing Li
MGMuxin Gong
Muxin Gong
Background: Heart failure (HF), the terminal stage of cardiovascular disease with high morbidity and mortality, remains poorly managed by current therapies. Ventricular remodeling in HF is fundamentally characterized by myocardial fibrosis. While ginsenoside Rb1 has demonstrated anti-fibrotic effects in HF, the underlying mechanism remains unclear. Twist1, an upstream regulator of energy metabolism factors PGC-1α and PPARα, may attenuate fibrosis by preserving systemic energy homeostasis, suggesting its pivotal role in HF pathogenesis. This study explores ginsenoside Rb1′s anti-HF mechanisms through the regulation of ginsenoside Rb1 on these metabolic regulators. Methods: Sprague Dawley rats were subjected to a ligation of the left anterior descending coronary artery to induce an HF model, followed by ginsenoside Rb1 treatment for 6 weeks. Therapeutic effects were evaluated through cardiac function assessment, myocardial histopathological staining (HE, Masson, immunofluorescence, immunohistochemistry), mitochondrial morphology observation (transmission electron microscopy), energy metabolism analysis (electron transport chain efficiency, mitochondrial membrane potential, ATP content), and protein expression profiling (Twist1, PGC-1α, PPARα, GLUT4, PPARγ). Additionally, H9c2 cells induced with endothelin-1 to model HF were employed as an in vitro model to further investigate ginsenoside Rb1′s regulatory effects on the Twist1/PGC-1α/PPARα signaling pathway. Results: Ginsenoside Rb1 can restore cardiac function in HF rats, improve mitochondrial function, alleviate energy metabolism disorders, and inhibit ventricular remodeling. By modulating the Twist1/PGC-1α/PPARα signaling pathway, ginsenoside Rb1 suppressed the abnormal overexpression of Twist1 and maintained normal expression of downstream PGC-1α and PPARα. In vitro experiments further demonstrated that ginsenoside Rb1 significantly inhibited Twist1 expression in H9c2 cardiomyocytes with HF while promoting PGC-1α and PPARα expression, thereby restoring myocardial energy metabolism and mitigating ventricular remodeling in HF. Conclusions: Ginsenoside Rb1 can inhibit the upregulation of Twist1 and activate the expression of its downstream PGC-1α and PPARα expression, by modulating the Twist1/PGC-1α/PPARα signaling pathway, alleviating ventricular remodeling in HF patients and improving myocardial energy metabolism dysfunction. Twist1 may be a key target for the treatment of HF. This study not only elucidates the mechanism by which ginsenoside Rb1 alleviates HF, but also provides new insights into the clinical treatment of HF.

22 May 2026 in Phytomedicine
Verified
Journal Article
Open access
ZZZiwei Zhou
Ziwei Zhou
QWQi Wang
Qi Wang
XGXiaomeng Guo
Xiaomeng Guo
ZSZhimin Song
Zhimin Song
ZZZekuan Zhang
Zekuan Zhang
MGMuxin Gong
Muxin Gong
Abnormal intercellular communication mediated by exosome (EXOs)-miRNAs in cardiac cells is the core pathogenic mechanism that induces myocardial energy metabolism disorders and leads to ventricular remodeling in heart failure (HF). Renshen Decoction (RSD), a traditional formula, exerts significant cardioprotective effects. However, whether it inhibits ventricular remodeling in HF by regulating EXOs-miRNA-mediated intercellular communication remains unclear. To explore the mechanism by which RSD improves myocardial energy metabolism disorders and inhibits ventricular remodeling in HF by regulating EXOs-miRNAs. In vivo experiments were conducted to observe the inhibitory effects of RSD on myocardial energy metabolism and ventricular remodeling in HF rats. Exosomal miRNA sequencing was performed using peripheral blood samples to screen for key EXOs-miRNAs mediating the effects of RSD on HF. In vitro, cardiac fibroblasts (CFs) were stimulated with endothelin-1. CF-derived EXOs were extracted and co-cultured with cardiomyocytes (CMs) to investigate the targeted regulatory effects of RSD on the candidate CFs-EXO-miRNA. RSD inhibited ventricular remodeling in HF rats by ameliorating myocardial energy metabolism disorder. Peripheral blood EXOs-miRNA sequencing identified miR-30e-5p as a key miRNA targeted by RSD. In vitro experiments revealed that RSD inhibited cardiomyocyte injury induced by CFs-EXOs-miR-30e-5p Additionally, RSD suppressed the abnormally high expression of the downstream targets of miR-30e-5p, including RARβ, SIRT1, BDNF, and FTO, in HF pathology. This study is the first to demonstrate that RSD may improve the energy metabolism disorder of CMs by regulating the CFs-EXOs-miR-30e-5p-RARβ/SIRT1/BDNF/FTO pathway, thereby inhibiting HF ventricular remodeling, which may provide new ideas for the treatment of HF.